Welcome to Seagull Pharmacy!
Mobile Version
Chinese Version
Drug
Article
dostarlimab
Sunrise
Androcur
Opzelura
Repatha
Pemazyre
All Drug Categories
Home
Anti-cancer Drugs
Healthcare Products
Medical Information
Statement
Common Medicines
Oncology
Hematology
Hepatology
Chronic Diseases
Department of Endocrinology
Orphan drugs
Others
Current Location:
Home
>
Orphan drugs
<<
<
0
>
>>
Jump to
Page
Medication Guidance
Medication Q&A
Popular Drugs
New Drugs
FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development
Sacituzumab Govitecan Significantly Improves PFS Vs Chemo in HR+ Metastatic Breast Cancer
Frontline Poziotinib Produces Clinically Meaningful Efficacy in NSCLC Harboring HER2 Exon 20 Insertion Mutations
Tamoxifen Plus Extended Letrozole Improves DFS in Postmenopausal Breast Cancer
Ivosidenib/Azacitidine Granted Priority Review Designation by FDA for IDH1+ AML
Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected Stage IIB and IIC Melanoma
First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria
Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer
Employers Highlight Barriers to Biosimilar Adoption
Biomarkers Allow for Tailoring TNBC Treatments
These three risk factors may have the biggest impact on dementia cases
pirfenex
Geftinat
Azilect
Twinaqt
Zurig
Sunrise
Lenvanix
Inbec
Lazertinib
pretomanid
letermovir
letermovir
Acalabrutinib
Acalabrutinib
Gilteritinib
Gilteritinib
pemigatinib
ivosidenib
ivosidenib
finerenone
mobocertinib
mobocertinib
Ruxolitinib
Ruxolitinib
Valcyte
Valcyte
Lorlatinib
Lorlatinib
larotrectinib
larotrectinib
Biktarvy
Capmatinib